Ghrelin
The endogenous 28-amino-acid 'hunger hormone' from the stomach — the natural ligand of GHS-R1a, the receptor that GHRP-2, GHRP-6, hexarelin, ipamorelin, and MK-677 all target. A research peptide and pharmacology reference, not a self-administered compound.
What is Ghrelin?
Ghrelin is a 28-amino-acid peptide hormone secreted primarily by X/A-like cells of the gastric fundus, with smaller amounts from the proximal small intestine. It circulates in two forms: acyl-ghrelin, the active form carrying an unusual octanoyl modification on Ser3 installed by ghrelin-O-acyltransferase (GOAT), and des-acyl ghrelin, which lacks the acyl modification and has distinct (still debated) biology. Acyl-ghrelin is the natural ligand of the growth hormone secretagogue receptor GHS-R1a, expressed in the hypothalamus, pituitary, and vagal afferents. Ghrelin is the only known circulating orexigenic (appetite-stimulating) hormone in humans — levels rise pre-meal and fall post-meal, and it drives both the subjective sensation of hunger and pituitary GH release. It is what the entire GHRP / GHS class of synthetic peptides (GHRP-2, GHRP-6, hexarelin, ipamorelin, MK-677) was designed to mimic.
What Ghrelin Is Investigated For
Ghrelin is primarily a biology-research and drug-target reference, not a self-administered peptide. Exogenous native ghrelin has been used in research and small clinical trials for cancer cachexia, anorexia nervosa, and functional GI disorders, but the commercial development pathway has focused on synthetic agonists — anamorelin for cancer cachexia, relamorelin for gastroparesis, and the older GHRP series for GH release — rather than native ghrelin itself. Ghrelin is not on compounded-peptide formularies, is not injected for wellness, and does not have a legitimate at-home use case. The interest from peptide-curious readers is usually upstream: understanding why GHRP-6 stimulates hunger, why post-bariatric patients lose their appetite, or what 'ghrelin resistance' actually means mechanistically. This page is positioned as a biology reference rather than a dosing guide.
History & Discovery
Ghrelin's discovery is the classical story of orphan-receptor pharmacology resolved years after the fact. Growth hormone secretagogues — synthetic peptides like GHRP-6 that drove pituitary GH release through what seemed to be a non-GHRH pathway — were developed in the 1980s by Cyril Bowers and collaborators. The receptor they bound was cloned by a Merck team (Howard et al.) in 1996 but remained an orphan — no endogenous ligand was known. In 1999 Masayasu Kojima and Kenji Kangawa, working at the National Cardiovascular Center Research Institute in Japan, isolated a 28-amino-acid peptide from rat stomach that activated the orphan receptor with high potency. They named it ghrelin, from the Proto-Indo-European root ghre- (to grow), because of its GH-release activity. The paper in Nature launched an enormous research program that quickly mapped ghrelin's orexigenic role (Tschöp 2000, Nakazato 2001), its pre-meal rise in humans (Cummings 2001), and its role in post-bariatric weight loss (Cummings 2002). The unusual octanoyl modification on Ser3 was puzzling for nearly a decade — until Yang et al. identified ghrelin-O-acyltransferase (GOAT/MBOAT4) in 2008 as the enzyme responsible. This raised the possibility of GOAT inhibition as an anti-obesity strategy, which was pursued but has not produced a clinically successful drug. The endogenous antagonist LEAP2 was identified as a GHS-R1a inverse agonist in 2018, shifting the field's understanding of ghrelin-receptor tone away from a simple agonist-only model. Therapeutic development has focused on synthetic agonists — anamorelin (cancer cachexia, approved in Japan 2020), relamorelin (gastroparesis, Phase 2/3), macimorelin (adult GHD diagnostic, FDA-approved 2017) — rather than on native ghrelin, which has not become a therapeutic itself.
How It Works
Ghrelin is the body's 'eat now' signal. It's made in the stomach, rises before meals, and tells the brain that it's time to look for food. The same receptor it activates (GHS-R1a) also triggers the pituitary to release growth hormone — which is why synthetic peptides built to mimic ghrelin (GHRP-2, GHRP-6, MK-677) are used as growth hormone secretagogues. Blocking ghrelin has been attempted as an obesity strategy but has not worked as dramatically as blocking GLP-1 receptors has as an appetite strategy.
Ghrelin is encoded by the GHRL gene and produced as a 117-amino-acid preproprotein that is processed to the mature 28-AA peptide. The critical post-translational event is octanoylation of Ser3 by ghrelin-O-acyltransferase (GOAT/MBOAT4), which requires dietary medium-chain fatty acids as acyl donors. Only the octanoylated form (acyl-ghrelin) activates GHS-R1a with high potency. GHS-R1a is a Gq-coupled receptor — it signals via PLC/IP3/DAG, raising intracellular calcium in target cells. In pituitary somatotrophs, this produces GH release. In the hypothalamic arcuate nucleus, GHS-R1a activation on NPY/AgRP neurons drives orexigenic signaling that overrides leptin/insulin-mediated satiety inputs. Vagal afferent fibers from the stomach also express GHS-R1a and may contribute to peripheral-to-central hunger signaling. The endogenous antagonist LEAP2 (liver-expressed antimicrobial peptide 2), identified as a ghrelin receptor inverse agonist in 2018, provides a counter-regulatory signal whose ratio with ghrelin may matter more than absolute ghrelin levels. GHS-R1a also forms heterodimers with dopamine D1 and D2 receptors in mesolimbic circuits, providing a molecular basis for ghrelin's involvement in food-reward and addiction-adjacent behaviors. Des-acyl ghrelin, which does not bind GHS-R1a, may have independent effects through an unidentified receptor, but the biology remains contested.
Evidence Snapshot
Human Clinical Evidence
Strong for ghrelin's physiologic role (appetite, GH release, pre-meal rise) and for the downstream implications (post-bariatric appetite changes). Moderate for anamorelin in cancer cachexia (approved in Japan, not the US) and relamorelin in functional dyspepsia/gastroparesis. Weak for ghrelin antagonism as obesity therapy — multiple programs have disappointed.
Animal / Preclinical
Extensive. GHS-R knockout mice, GOAT-knockout mice, and LEAP2-manipulation studies have mapped the signaling axis in detail. Rodent work anchors the current understanding of ghrelin's role in food reward, stress eating, and GH pulsatility.
Mechanistic Rationale
Strong. GHS-R1a pharmacology, GOAT enzymology, and central vs peripheral signaling are well-characterized. Recent cryo-EM structures of GHS-R1a bound to ghrelin and to synthetic agonists have clarified the binding-pocket architecture.
Research Gaps & Open Questions
What the current literature has not yet settled about Ghrelin:
- 01The biological function of des-acyl ghrelin — which circulates at higher levels than acyl-ghrelin but does not bind GHS-R1a — remains incompletely characterized despite over two decades of investigation.
- 02Why ghrelin-receptor blockade has repeatedly failed to deliver meaningful weight loss in obesity, given the strong appetite-stimulating effect of agonists.
- 03The therapeutic potential of GOAT inhibition — an attractive target on paper but a drug development path with recurring disappointments.
- 04The role of ghrelin in food reward and addiction-adjacent behaviors beyond simple hunger, including proposed roles in alcohol-use disorder and stress-induced eating.
- 05Long-term consequences of chronic GHS-R1a agonism in healthy populations — the existing human data (largely from the GHRP series used in research since the 1990s) does not adequately address long-term cancer, cardiometabolic, or GH-axis consequences.
- 06The LEAP2-to-ghrelin ratio as a potentially more informative biomarker than absolute ghrelin levels, and whether therapeutic modulation of this ratio (rather than pure ghrelin blockade) could produce weight-loss effects.
Forms & Administration
Native acyl-ghrelin is not available as a pharmaceutical. Research use involves intravenous or subcutaneous infusion of recombinant peptide in controlled study settings. Therapeutic development has focused on synthetic small-molecule and peptide agonists (anamorelin — approved in Japan for cancer cachexia; relamorelin — Phase 2/3 in gastroparesis) or on the synthetic GHRP series (GHRP-2, GHRP-6, MK-677) that has been in research and grey-market use for decades. Macimorelin (Macrilen) is the only FDA-approved GHS-R1a agonist, used diagnostically in a single-oral-dose adult GHD stimulation test. 'Research grade' ghrelin sold by chemistry suppliers is not a legitimate therapeutic source.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Native ghrelin is not a therapeutic and has no approved dosing protocol. Research infusions in controlled studies typically used 1–5 mcg/kg IV bolus or continuous infusion at similar dose ranges. Therapeutic ghrelin-pathway drugs have their own regimens: anamorelin 100 mg oral once daily (Japan approval); relamorelin 10 mcg SC twice daily in trials; macimorelin 0.5 mg/kg oral single dose for diagnostic GHD testing.
Frequency
Native ghrelin has a very short plasma half-life (under 30 minutes for acyl-ghrelin), which is why research use required infusion and why synthetic analogs were developed. Endogenous ghrelin itself cycles pre-meal to post-meal on the order of hours.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Protocol Notes
There is no legitimate at-home use of native ghrelin. If you are looking for a ghrelin-pathway compound, the pharmacologically relevant options are the synthetic GHS-R1a agonists: GHRP-2, GHRP-6, hexarelin, ipamorelin, MK-677, and the approved diagnostic macimorelin — each covered as a separate entry. Research-grade ghrelin sold online is not a therapeutic and has no established use pattern. Endogenous ghrelin biology is genuinely interesting, and understanding it explains why compounds in this class behave the way they do, but ghrelin itself is not the tool.
Ghrelin is a research peptide, not a therapeutic or supplement. Nothing on this page constitutes a suggested self-use protocol.
Timeline of Effects
Onset
When administered in research settings, ghrelin produces GH release within 15–30 minutes and a measurable increase in subjective hunger within 30–60 minutes of an IV bolus. Its plasma half-life is under 30 minutes for the active acyl form.
Peak Effect
Peak GH release typically occurs 30–60 minutes after ghrelin administration. Subjective hunger peaks in a similar window and declines over 1–2 hours as the peptide is cleared.
After Discontinuation
Because of the short half-life, effects resolve within 1–2 hours of the end of infusion. There is no recognized post-exposure adaptation from a single administration. Chronic exposure models (rodent) show receptor desensitization, which is partly why the synthetic long-acting agonists (particularly MK-677) have more complex tolerance profiles than the short-acting native peptide.
Monitoring & Measurement
Bloodwork & Labs
- •Plasma acyl-ghrelin by specific immunoassay (protease-inhibitor tube required — ghrelin degrades rapidly in standard serum)
- •Plasma total ghrelin (less informative than acyl-specific)
- •Serum IGF-1 (downstream of GH release — more stable readout of ghrelin-axis activity)
- •LEAP2 (emerging research biomarker, not yet clinical)
Functional & Performance Tests
- •Response to a ghrelin-receptor-agonist challenge (macimorelin test) — indirect measure of pituitary GH reserve
When to Test
For any ghrelin-related clinical question, fasting morning samples are standard. Acyl-ghrelin requires rapid processing with protease inhibitors because the octanoyl group is labile.
Interpretation & Notes
Ghrelin assays are notoriously dependent on specimen handling. Standard serum tubes without protease inhibitors preserve total ghrelin but allow acyl-ghrelin to degrade within minutes. Studies that do not specify tube type or processing conditions should be interpreted cautiously. For clinical use, ghrelin measurement is rarely informative — the more useful downstream markers are IGF-1 (for the GH arm of ghrelin signaling) and standard metabolic panels. Macimorelin stimulation testing for adult GHD is the one clinically useful application of ghrelin-receptor pharmacology in routine endocrine practice.
Common Questions
Who Ghrelin Is NOT For
- •Active malignancy — ghrelin is growth-factor-adjacent and chronic stimulation of the GH/IGF-1 axis is generally avoided in active cancer.
- •Untreated severe diabetes or diabetic ketoacidosis — the GH-release effect worsens insulin resistance.
- •Pregnancy — ghrelin has not been studied therapeutically in pregnancy and is not appropriate for self-administration in any context.
- •Children and adolescents — ghrelin-pathway manipulation in developing individuals is not appropriate outside specifically indicated clinical trials.
Drug & Supplement Interactions
Native ghrelin is not a therapeutic and therefore does not have a classical interaction profile. For ghrelin-receptor-agonist drugs in the class (anamorelin, relamorelin, macimorelin, and the GHRP series), interactions overlap: all drive transient GH and cortisol release, raising insulin and oral-antihyperglycemic requirements in diabetic patients; all may interact with other GH axis agents (rhGH, sermorelin, CJC-1295) if co-administered; and all share the consideration that chronic GH-axis stimulation alters hepatic metabolism and can modestly affect P450-dependent drug clearance. Macimorelin specifically has a QT-prolongation warning and interacts with strong CYP3A4 inhibitors. The short plasma half-life of native ghrelin limits sustained interaction potential in research settings.
Safety Profile
Common Side Effects
Cautions
- • Not available as a legitimate therapeutic or supplement — this is a biology reference
- • Synthetic ghrelin receptor agonists (anamorelin, relamorelin) have their own distinct safety profiles
- • Chronic activation of GHS-R1a drives sustained GH elevation, with the usual insulin-resistance and fluid-retention implications
What We Don't Know
The role of des-acyl ghrelin — which circulates at higher levels than acyl-ghrelin but does not bind GHS-R1a — remains incompletely understood. Proposed functions include glucose modulation, bone effects, and central actions through an as-yet-uncharacterized receptor, but consensus on its biological significance has not converged.
Legal Status
United States
Native ghrelin is not a scheduled controlled substance and is not an approved drug. Its sale as a 'research chemical' is in a grey area — it is not a legitimate therapeutic and is not on any FDA-approved or compounded-peptide formulary. The downstream synthetic agonists (GHRP-2/6, hexarelin, ipamorelin, MK-677, macimorelin, anamorelin) each have their own regulatory status detailed on their individual pages.
International
Largely parallel to US status — native ghrelin is a research compound without established therapeutic use. Macimorelin is approved in the US and EU as a diagnostic. Anamorelin is approved in Japan for cancer cachexia under the brand Adlumiz.
Sports & Competition
GHS-R1a agonists — including ghrelin itself and all synthetic mimetics — are explicitly banned under WADA's S2 class (peptide hormones, growth factors, related substances and mimetics). Detection is principally via the same GH isoform and biomarker tests used for rhGH, plus direct assays for specific synthetic agonists.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Blocking ghrelin is a promising obesity treatment.
Reality
It has been attempted multiple times and has consistently underperformed expectations. The LEAP2 discovery in 2018 raised hopes for endogenous antagonism, but neither synthetic ghrelin antagonists nor GOAT inhibitors have produced the weight-loss magnitude seen with GLP-1 agonists. The drug-development money has largely moved to multi-agonist GLP-1/GIP/glucagon approaches.
Myth
Fasting makes ghrelin skyrocket permanently.
Reality
Ghrelin rises with acute caloric deprivation but adapts over longer fasting windows. Several studies have shown that extended fasting (multiple days) does not produce runaway ghrelin elevation, and that chronic caloric restriction has a more complex effect on ghrelin set-point than the acute picture suggests.
Myth
Ghrelin is only about hunger.
Reality
Ghrelin drives GH release, modulates glucose metabolism, affects mesolimbic reward processing, has proposed roles in memory and stress resilience, and contributes to gastric emptying. The appetite role is the most famous but far from the only function.
Myth
You can take oral ghrelin supplements to stimulate GH.
Reality
Native ghrelin is a peptide that degrades rapidly in the GI tract and is not orally bioavailable. No oral ghrelin supplement exists. The orally-active compounds in this class are small molecules (MK-677 / ibutamoren, macimorelin, anamorelin) engineered specifically for oral absorption — not ghrelin itself.
Myth
GHRP-6 is just synthetic ghrelin.
Reality
GHRP-6 and ghrelin activate the same receptor (GHS-R1a) but have different structures, different pharmacokinetics, and different secondary effects. GHRP-6 is a six-residue synthetic peptide; ghrelin is a 28-residue octanoylated peptide. They are not interchangeable at the molecular level, even if they produce similar downstream GH release.
Published Research
12 studiesStructural basis for recognition of ghrelin and its receptor
Shiimura et al. 2021 — cryo-EM structures of the ghrelin-GHS-R1a complex clarifying the binding-pocket architecture and providing a structural basis for designing selective agonists and antagonists.
LEAP2 is an endogenous antagonist of the ghrelin receptor
Ge et al. 2018 Cell Metabolism — identified LEAP2 (liver-expressed antimicrobial peptide 2) as an endogenous inverse agonist of GHS-R1a, establishing a counter-regulatory axis that shifts the field's understanding of ghrelin-receptor tone.
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2)
Temel et al. 2016 Lancet Oncology — pivotal Phase 3 trials of the oral ghrelin receptor agonist anamorelin in cancer cachexia, showing improved lean body mass but inconsistent strength endpoints. Led to approval in Japan; FDA did not approve.
Macimorelin as a diagnostic test for adult growth hormone deficiency
Garcia et al. 2013 JCEM — pivotal data on macimorelin, a synthetic oral ghrelin receptor agonist, as a stimulation test for adult GHD diagnosis. The only FDA-approved GHS-R1a agonist.
Ghrelin directly targets the ventral tegmental area to increase food motivation
Skibicka et al. 2012 Addiction Biology — showed that ghrelin acts on mesolimbic reward circuits (VTA) to drive food-motivated behavior independent of hypothalamic hunger signaling, providing a mechanism for ghrelin's involvement in reward and addiction-adjacent behaviors.
Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone
Yang et al. 2008 Cell — identified ghrelin-O-acyltransferase (GOAT/MBOAT4) as the enzyme that installs the octanoyl modification required for GHS-R1a activation. Central to understanding ghrelin post-translational biology.
Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery
Cummings et al. 2002 NEJM — showed that diet-induced weight loss raises ghrelin (defending against weight regain) while gastric bypass substantially suppresses it, helping explain the durable appetite suppression after bariatric surgery.
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings et al. 2001 Diabetes — established that human plasma ghrelin rises sharply before spontaneous meals and falls postprandially, consistent with a meal-initiation role.
A role for ghrelin in the central regulation of feeding
Nakazato et al. 2001 Nature — showed that intracerebroventricular ghrelin drives food intake via hypothalamic NPY/AgRP neurons and that ghrelin receptor antagonism blocks feeding responses. Core mechanistic paper.
Ghrelin induces adiposity in rodents
Tschöp et al. 2000 Nature — demonstrated that chronic ghrelin administration in rodents induces weight gain and adiposity independent of GH, establishing the orexigenic role distinct from the GH-release effect.
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima et al. 1999 Nature — the original discovery paper identifying ghrelin from rat stomach as the endogenous ligand for the orphan GHS-R1a receptor. The foundation of the entire field.
A receptor in pituitary and hypothalamus that functions in growth hormone release
Howard et al. 1996 Science — cloning of the growth hormone secretagogue receptor (GHS-R1a), which was an orphan receptor until ghrelin was identified as its endogenous ligand three years later.
Quick Facts
- Class
- Gut Hormone
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 12PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.